MID-1
CAS No. : 312608-54-1
| Size | Price | Stock |
|---|---|---|
| 5mg | $160 | In-stock |
| 10mg | $260 | In-stock |
| 25mg | $465 | In-stock |
| 50mg | $700 | In-stock |
| 100mg | $980 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-115461 |
| M.Wt: | 293.30 |
| Formula: | C12H11N3O4S |
| Purity: | >98 % |
| Solubility: | DMSO : 31.25 mg/mL (ultrasonic) |
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake[1].
In Vitro: MID-1 (5 μM; 24 h) increases the IRS-1 expression level in skeletal muscle by disrupting the MG53-IRS-1 interaction[1].
MID-1 (10 μM; 12 h) reduces the luciferase activity in HEK 293 cell line expressing NLUC-IRS-1 and CLUC-C14A[1].
MID-1 (1-20 μM; 12 h) disrupts the MG53-IRS-1 interaction but not MG53-FAK interaction in HEK 293 cells[1].
MID-1 (0.1-10 μM; 4-24 h) abolishes MG53-induced IRS-1 ubiquitination and degradation in HEK 293 cells[1].
MID-1 (5-10 μM; 24 h) increases insulin signaling and insulin-elicited glucose uptake in C2C12 myotubes[1].
MID-1 (5-10 μM; 24 h) enhances skeletal myogenesis[1].
In Vivo: MID-1 does not have good pharmacokinetics in vivo[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- MID-1
- Cat. No.:
- HY-115461
- Quantity:
Your information is safe with us.